10205. Teduglutide

Nomenclature

CAS number: 197922-42-2
l-Histidylglycyl-l-α-aspartylglycyl-l-seryl-l-phenylalanyl-l-seryl-l-α-aspartyl-l-α-glutamyl-l-methionyl-l-asparaginyl-l-threonyl-l-isoleucyl-l-leucyl-l-α-aspartyl-l-asparaginyl-l-leucyl-l-alanyl-l-alanyl-l-arginyl-l-α-aspartyl-l-phenylalanyl-l-isoleucyl-l-asparaginyl-l-tryptophyl-l-leucyl-l-isoleucyl-l-glutaminyl-l-threonyl-l-lysyl-l-isoleucyl-l-threonyl-l-aspartic acid; glucagon-like peptide II [2-glycine] (human); h[Gly2]GLP-2; ALX-0600.
C164H252N44O55S; mol wt 3752.08.
C 52.50%, H 6.77%, N 16.43%, O 23.45%, S 0.85%.

Description and references

Analog of glucagon-like peptide II, q.v., that is resistant to enzymatic degradation by dipeptidylpeptidase (DPP) IV. Induces mucosal epithelial proliferation in the gastrointestinal tract. Prepn: D. J. Drucker et al., WO 97 39031; eidem, US 5789379 (1997, 1998 both to Allelix). Resistance to DPP-IV: P. L. Brubaker et al., Endocrinology 138, 4837 (1997) DOI PubMed. Intestinotrophic activity: C. Booth et al., Cell Prolif. 37, 385 (2004) DOI PubMed. Clinical trial in short bowel syndrome: P. B. Jeppesen et al., Gut 54, 1224 (2005) DOI PubMed. Review of pharmacology and clinical development: M. Ferrone, J. S. Scolapio, Ann. Pharmacother. 40, 1105-1109 (2006) DOI PubMed.

Chemical structure

Therapeutic Category

In treatment of short bowel syndrome.